Table 3.
Most cited papers.
| No | Title | Total Citation | Published Year | Cite Rate |
|---|---|---|---|---|
| 1 | The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease | 2046 | 2004 | 136.4 |
| 2 | A 4-year trial of tiotropium in chronic obstructive pulmonary disease | 1390 | 2008 | 126.4 |
| 3 | Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. | 1298 | 2010 | 144.2 |
| 4 | Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease | 1223 | 1998 | 58.2 |
| 5 | Randomised, double blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial* | 964 | 2000 | 50.7 |
| 6 | Development and first validation of the COPD Assessment Test | 933 | 2009 | 93.3 |
| 7 | Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease | 868 | 2005 | 62.0 |
| 8 | Outcomes following acute exacerbation of severe chronic obstructive lung disease | 863 | 1996 | 37.5 |
| 9 | Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial | 749 | 2003 | 46.8 |
| 10 | Chronic obstructive pulmonary disease: current burden and future projections | 698 | 2006 | 53.7 |
| 11 | Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease | 655 | 2000 | 34.5 |
| 12 | A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease | 609 | 2002 | 35.8 |
| 13 | Azithromycin for Prevention of Exacerbations of COPD | 578 | 2011 | 72.3 |
| 14 | Reduction of hospital utilization in patients with chronic obstructive pulmonary disease—A disease-specific self-management intervention | 576 | 2003 | 36.0 |
| 15 | Effects of pulmonary rehabilitation on physiological and psychosocial outcomes in patients with chronic obstructive pulmonary disease | 568 | 1995 | 23.7 |
| 16 | Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease | 550 | 2003 | 34.4 |
| 17 | Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial | 536 | 2000 | 28.2 |
| 18 | Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD | 500 | 2002 | 29.4 |
| 19 | Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium | 492 | 2002 | 28.9 |
| 20 | Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease | 472 | 2003 | 29.5 |
| 21 | Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report | 467 | 2017 | 233.5 |
| 22 | Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations | 458 | 2000 | 24.1 |
| 23 | Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease—A randomized trial | 448 | 2007 | 37.3 |
| 24 | Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease | 443 | 1996 | 19.3 |
| 25 | Risk factors of readmission to hospital for a COPD exacerbation: a prospective study | 421 | 2003 | 26.3 |
| 26 | Mortality after hospitalization for COPD | 380 | 2002 | 22.4 |
| 27 | Depressive symptoms and chronic obstructive pulmonary disease—Effect on mortality, hospital readmission, symptom burden, functional status, and quality of life | 369 | 2007 | 30.8 |
| 28 | How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer | 338 | 2000 | 17.8 |
| 29 | Randomized controlled trial of respiratory rehabilitation | 337 | 1994 | 13.5 |
| 30 | Early therapy improves of chronic obstructive outcomes of exacerbations pulmonary disease | 335 | 2004 | 22.3 |
| 31 | Quality of life changes in COPD patients treated with salmeterol | 331 | 1997 | 15.0 |
| 32 | Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities | 323 | 2009 | 32.3 |
| 33 | A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol | 323 | 2002 | 19.0 |
| 34 | Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD | 317 | 2003 | 19.8 |
| 35 | Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial | 315 | 2005 | 22.5 |
| 36 | Analysis of the factors related to mortality in chronic obstructive pulmonary disease—Role of exercise capacity and health status | 314 | 2003 | 19.6 |
| 37 | Interpreting thresholds for a clinically significant change in health status in asthma and COPD | 313 | 2002 | 18.4 |
| 38 | Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: A randomized trial | 308 | 2000 | 16.2 |
| 39 | Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study | 299 | 2004 | 19.9 |
| 40 | Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease | 298 | 2005 | 21.3 |
Note: * The inhaled steroids in obstructive lung disease in Europe (ISOLDE).